title: Side effects of cyclosporine-A treatment in rats: gingival overgrowth and early hyperglycemia.
abstract: Gingival overgrowth is an adverse side effect of cyclosporine A (CsA) in the treatment of transplanted patients. The purpose of this study was to evaluate the effects of CsA on new-onset diabetes mellitus and gingival overgrowth in rats, by measuring collagen, nitric oxide and microvascular permeability. Blood glucose level, collagen, nitric oxide level and vascular permeability were determined. Blood glucose level increased significantly from 6.5 +/- 0.9 for the control group to 15 +/- 1.2, 17 +/- 1.2 and 21.6 +/- 1.6 mM/L at 1, 4 or 8 weeks of CsA treatment, respectively. Collagen (ug HO Proline/mg p) increased significantly from 2.5 +/- 0.5 for the control group to 4.2 +/- 0.8, 5.9 +/- 0.6 and 7.3 +/- 0.8 at 1, 4 or 8 weeks of CsA treatment, respectively. Vascular permeability was 10.3 +/- 1.2 for the control group and 15 +/- 1; 17.2 +/- 1.3, and 22.1 +/- 2.1 ug EB/g T; at 1, 4 or 8 weeks of CsA treatment, respectively Nitric oxide level was 3.5 +/- .9 umol/mg P for the control group and 4 +/- 0.2, 8.2 +/- 0.9 and 11 +/- 1 for 1, 2 or 8 weeks of CsA treatment, respectively. These findings appear to indicate that the development of significant gingival changes induced by CsA is related to new-onset of diabetes mellitus during the immunosuppressive treatment.
authors.affiliation: Department of Biochemistry-School of Dentistry, John F Kennedy University, USA. Ocatan50@aol.com
authors.forename: Orlando L
authors.initials: OL
authors.lastname: Catanzaro
authors.forename: Lorena Calvo
authors.initials: LC
authors.lastname: Lauria
authors.forename: Pablo
authors.initials: P
authors.lastname: Obregon
authors.forename: Emilio S
authors.initials: ES
authors.lastname: Labal
authors.forename: Ricardo R
authors.initials: RR
authors.lastname: Rodriguez
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000032:analysis / Q000187:drug effects; D002199:Capillary Permeability / Q000187:drug effects; D003094:Collagen / Q000032:analysis / Q000187:drug effects; D004396:Coloring Agents; D016572:Cyclosporine / Q000009:adverse effects*; D003920:Diabetes Mellitus / Q000139:chemically induced; D005070:Evans Blue; D005881:Gingiva / Q000187:drug effects / Q000473:pathology; D019214:Gingival Overgrowth / Q000139:chemically induced*; D006943:Hyperglycemia / Q000139:chemically induced*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008297:Male; D009569:Nitric Oxide / Q000032:analysis; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D004396:Coloring Agents; D007166:Immunosuppressive Agents; D009569:Nitric Oxide; D005070:Evans Blue; D016572:Cyclosporine; D003094:Collagen